Clinicopathological features of breast cancer with different molecular subtypes in chinese women

Abstract

A retrospective study was performed to explore the relationship between molecular subtypes and clinicopathological features of breast cancer in Chinese women. Six hundred and twenty-eight Chinese women with breast cancer were classified into four molecular subtypes according to their estrogen receptor (ER), progesterone receptor (PR) and Her-2 status. The prevalence rate of each molecular subtype was analyzed. Relationship between the subtypes and clinicopathologic features was determined. The distribution of molecular subtypes was as follows: luminal A 46.5%, luminal B 17.0%, basal 21.5%, HER2/neu 15.0%. The subtypes had no significant difference under different menopausal status. However, in the age-specific groups, the age group of ≤35 years was more likely to get basal cell-like cancer (36.9%). Statistically significant differences were found among molecular subtypes by age, nuclear grade, tumor size, lymph node (LN) metastasis, tumor stage by American Joint Committee on Cancer (AJCC), radiotherapy but not by chemotherapy, types of surgery. After adjusting for several relative confounding factors, the basal subtype more likely had lower nodal involvement in both the incidence of LN metastasis (≥1 positive LN) and incidence of high-volume LN metastasis (≥4 positive LN). The HER2/neu subtype had higher nodal involvement in the incidence of high-volume LN metastases. After adjusting for relative confounding factors, the HER2/neu subtype more likely had higher AJCC tumor stages. It was suggested that there existed close relationship between molecular subtypes and clinicopathological features of breast cancer. In addition, the breast cancer subtypes have been proven to be an independent predictor of LN involvement and AJCC tumor stage. These findings are very important for understanding the occurrence, development, prognosis and treatment of breast cancer in Chinese population.

Keywords

breast cancer / molecular subtypes / clinicopathological features

References

[1] GreenleeR.T., MurrayT., BoldenS., et al.. Cancer statistics, 2000. CA Cancer J Clin, 2000, 50(1): 7-33

[2] TavassoliF.A., SchnittS.J.. . Pathology of the breast, 1992, New York, Elsevier, 27-36

[3] WienckeJ.K.. Opinion: Impact of race/ethnicity on molecular pathways in human cancer. Nat Rev Cancer, 2004, 4(1): 79-84

[4] SorlieT., TibshiraniR., ParkerJ., et al.. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 2003, 100(14): 8418-8423

[5] BrentonJ.D., CareyL.A., AhmedA.A., et al.. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol, 2005, 23(29): 7350-7360

[6] NguyenP.L., TaghianA.G., KatzM.S., et al.. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast conserving therapy. J Clin Oncol, 2008, 26(14): 2373-2378

[7] RouzierR., PerouC.M., SymmansW.F., et al.. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res, 2005, 11(16): 5678-5685

[8] VoducK.D., CheangM.C.U., TyldesleyS., et al.. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol, 2010, 28(10): 1684-1691

[9] PerouC.M., SorlieT., EisenM.B., et al.. Molecular portraits of human breast tumors. Nature, 2000, 406(6797): 747-752

[10] SorlieT., PerouC.M., TibshiraniR., et al.. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 2001, 98(19): 10 869-10 874

[11] WiecmannL., SampsonM., StempelM., et al.. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol, 2009, 16(10): 2705-2710

[12] BlackmanD.J., MasiC.M.. Racial and ethnic disparities in breast cancer mortality: Are we doing enough to address the root causes?. J Clin Oncol, 2006, 24(14): 2170-2178

[13] CrabbS.J., CheangM.C., LeungS., et al.. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer, 2008, 8(3): 249-256

[14] RakhaE.A., El-SayedM.E., GreenA.R., et al.. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109(1): 25-32

[15] HafftyB.G., YangQ., ReissM., et al.. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 2006, 24(36): 5652-5657

[16] KimM.J., RoJ.Y., AhnS.H., et al.. Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neu-over-expressing phenotypes. Hum Pathol, 2006, 37(9): 1217-1226

[17] KurebayashiJ., MoriyaT., IshidaT., et al.. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast, 2007, 16(suppl2): s72-77

[18] IhemelanduC.U., LeffallL.D.Jr, DewittyR.L., et al.. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res, 2007, 143(1): 109-118

[19] ChlebowskiR.T., ChenZ., AndersonG.L., et al.. Ethnicity and breast cancer: Factors influencing differences in incidence and outcome. J Natl Cancer Inst, 2005, 97(6): 439-448

[20] NielsenT.O., HsuF.D., JensenK., et al.. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 2004, 10(16): 5367-5374

[21] CareyL.A., PerouC.M., LivasyC.A., et al.. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA, 2006, 295(21): 2492-2502

[22] RakhaE.A., El-RehimD.A., PaishC., et al.. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer, 2006, 42(18): 3149-3156